AMLX (STOCKS)
Amylyx Pharmaceuticals, Inc. Common Stock
$14.350000
-0.540000 (-3.63%)
Prev close: $14.890000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Joshua B. Cohen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,679.66M
- Employees
- 123
- P/E (TTM)
- -8.27
- P/B (TTM)
- 4.92
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.37 | $-0.46 | +0.0889 | +19.37% |
|
Jun 2025 (Q2)
|
$-0.46 | $-0.45 | -0.0060 | -1.32% |
|
Mar 2025 (Q1)
|
$-0.42 | $-0.48 | +0.0645 | +13.31% |
|
Dec 2024 (Q4)
|
$-0.55 | $-0.53 | -0.0196 | -3.70% |
Financial Statements
| Revenues | -$665.00K |
| Cost Of Revenue | $0.00 |
| Costs And Expenses | $156.68M |
| Nonoperating Income/Loss | $7.42M |
| Selling, General, and Administrative Expenses | $64.59M |
| Research and Development | $92.08M |
| Operating Income/Loss | -$157.34M |
| Income/Loss From Continuing Operations After Tax | -$149.28M |
| Income/Loss From Continuing Operations Before Tax | -$149.92M |
| Income Tax Expense/Benefit | -$635.00K |
| Net Income/Loss | -$149.28M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$149.28M |
| Net Income/Loss Available To Common Stockholders, Basic | -$149.28M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.79 |
| Diluted Earnings Per Share | -$1.79 |
| Basic Average Shares | 89,569,050 |
| Diluted Average Shares | 89,569,050 |
| Assets | $362.74M |
| Current Assets | $353.38M |
| Noncurrent Assets | $9.36M |
| Fixed Assets | $399.00K |
| Other Non-current Assets | $8.96M |
| Liabilities | $30.75M |
| Current Liabilities | $25.79M |
| Accounts Payable | $5.34M |
| Wages | $9.81M |
| Other Current Liabilities | $10.65M |
| Noncurrent Liabilities | $4.95M |
| Equity | $332.00M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $332.00M |
| Liabilities And Equity | $362.74M |
| Net Cash Flow From Operating Activities | -$154.45M |
| Net Cash Flow From Operating Activities, Continuing | -$154.45M |
| Net Cash Flow From Investing Activities | $49.55M |
| Net Cash Flow From Investing Activities, Continuing | $49.55M |
| Net Cash Flow From Financing Activities | $257.35M |
| Net Cash Flow From Financing Activities, Continuing | $257.35M |
| Exchange Gains/Losses | $431.00K |
| Net Cash Flow | $152.88M |
| Net Cash Flow, Continuing | $152.45M |
| Comprehensive Income/Loss | -$149.11M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$149.11M |
| Other Comprehensive Income/Loss | -$34.21M |
| Other Comprehensive Income/Loss Attributable To Parent | $174.00K |